|Composition :||100mg/ ml (100ml pack)|
|Indications :||Treatment of partial onset seizures in adults with epilepsy.|
|Contraindications :||Hypersensitivitiy to levetiracetam or other pyrrolidone derivatives.|
|Safety Profile :||Should be withdrawn gradually to minimize the potential of increased seizure frequency. |
Caution required in patient with moderate and severe renal impairment and patients undergoing hemodialysis. Assessment of renal function is recommended before selection. Driving or operating machinery is not recommended.
|Adverse Effects :||Headache, anxiety, depression, dizziness, somnolence, increase cough, convulsion, vertigo, hallycination, irritability psychotic disorder, thromobocytopenia, neutropenia, leukopenia.|
|Drug Interactions:||It does not influence the plasma concentration of existing AEDs (like phenytoin)and these AEDs do not influence the pharma cokinetics of levetiracetam.|
|Dosage :||Intial dose 1000 mg / day B.I.D depending upon the tolerance and response. Incremental dose is 1000 mg day additional every 2 weeks. |
Maximum doses 3000 mg / day.
Dose should be withdraw gradually e.g . 500 mg twice daily decrements every 2-4 weeks.
|Purity :||Not less than 99%.|
|Also gives||PCD Pharma Franchise, Third Party Manufacturing|